127.56
Schlusskurs vom Vortag:
$127.12
Offen:
$127.22
24-Stunden-Volumen:
1.56M
Relative Volume:
0.71
Marktkapitalisierung:
$13.55B
Einnahmen:
$612.78M
Nettoeinkommen (Verlust:
$-86.37M
KGV:
-146.62
EPS:
-0.87
Netto-Cashflow:
$-62.91M
1W Leistung:
+0.52%
1M Leistung:
+34.46%
6M Leistung:
+73.29%
1J Leistung:
+75.29%
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Firmenname
Intra Cellular Therapies Inc
Sektor
Telefon
(646) 440-9333
Adresse
135 ROUTE 202/206, BEDMINSTER, NY
Vergleichen Sie ITCI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ITCI
Intra Cellular Therapies Inc
|
127.56 | 13.55B | 612.78M | -86.37M | -62.91M | -0.87 |
![]()
ZTS
Zoetis Inc
|
174.29 | 78.63B | 9.15B | 2.43B | 2.31B | 5.32 |
![]()
HLN
Haleon Plc Adr
|
9.85 | 44.54B | 14.26B | 1.55B | 0 | 0.3383 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 42.61B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.59 | 18.79B | 16.54B | -1.64B | 749.00M | -1.45 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-31 | Herabstufung | Canaccord Genuity | Buy → Hold |
2024-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
2023-12-11 | Eingeleitet | TD Cowen | Outperform |
2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
2022-08-22 | Herabstufung | Goldman | Buy → Neutral |
2022-07-07 | Eingeleitet | Mizuho | Buy |
2022-06-14 | Eingeleitet | UBS | Buy |
2022-04-22 | Eingeleitet | Piper Sandler | Neutral |
2022-02-16 | Eingeleitet | Goldman | Buy |
2021-09-23 | Eingeleitet | Needham | Buy |
2020-12-15 | Eingeleitet | BofA Securities | Buy |
2020-12-10 | Eingeleitet | Goldman | Buy |
2020-02-20 | Eingeleitet | Evercore ISI | Outperform |
2020-01-31 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-12-24 | Bestätigt | Canaccord Genuity | Buy |
2019-08-12 | Eingeleitet | Jefferies | Buy |
2018-02-26 | Eingeleitet | JP Morgan | Overweight |
2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
2017-11-08 | Hochstufung | SunTrust | Hold → Buy |
2017-09-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
2017-08-30 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2017-08-24 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2017-08-23 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
2017-05-02 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2017-05-02 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
2017-05-01 | Herabstufung | Piper Jaffray | Overweight → Neutral |
2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
2016-09-29 | Bestätigt | RBC Capital Mkts | Outperform |
2016-09-29 | Herabstufung | SunTrust | Buy → Neutral |
Alle ansehen
Intra Cellular Therapies Inc Aktie (ITCI) Neueste Nachrichten
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
abrdn plc Has $19.13 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Lessened by Calamos Advisors LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Growth in Short Interest - MarketBeat
UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating - Marketscreener.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
KBC Group NV Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 5.3% in January - Defense World
Canaccord cuts Intra-Cellular stock rating, raises target to $132 - MSN
Intra-Cellular Therapies (NASDAQ:ITCI) Cut to “Hold” at Canaccord Genuity Group - Defense World
Moody Aldrich Partners LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
R Squared Ltd Takes $205,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
SG Americas Securities LLC Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119 - Marketscreener.com
SG Americas Securities LLC Buys 8,673 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - MSN
Merit Financial Group LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - MSN
Finanzdaten der Intra Cellular Therapies Inc-Aktie (ITCI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intra Cellular Therapies Inc-Aktie (ITCI) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Option Exercise |
12.73 |
51,000 |
649,230 |
1,121,329 |
Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Sale |
85.80 |
51,000 |
4,375,659 |
1,070,329 |
Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Sale |
84.08 |
51,697 |
4,346,842 |
1,070,329 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):